Weight Loss

Skye Bioscience, Inc. (NASDAQ:SKYE) on Monday shared interim 52-week data from the combination therapy arms in the extension phase of the Phase 2a CBeyond proof-of-concept study of nimacimab. Skye Phase 2a clinical trial (NCT06577090) in obesity for nimacimab, is a negative allosteric modulating...

Novo Nordisk A/S (NYSE:NVO) sharply increased its U.S. advertising spend on its blockbuster GLP-1 drugs Wegovy and Ozempic in 2025, outpacing rival Eli Lilly and Co (NYSE:LLY) as competition for market share in the obesity and diabetes space intensified, according to data reviewed by Reuters....

Novo Nordisk A/S (NYSE:NVO) is accused of unlawfully extending its monopoly over its diabetes drug Victoza through a multiyear anticompetitive scheme designed to delay generic competition. • What’s ahead for NVO stock? The class action complaint, filed in the U.S. District Court,...

On Friday, AstraZeneca Plc (NASDAQ:AZN) announced that it has strengthened its weight management portfolio through a new strategic collaboration agreement with CSPC Pharmaceuticals Group Limited to advance the development of multiple next-generation therapies for obesity and type 2 diabetes across...

Roche Holdings AG (OTC:RHHBY) on Tuesday released topline results from the CT388-103 Phase 2 trial of CT-388 for obesity. CT-388 is an investigational once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist being developed for the treatment of obesity, type 2 diabetes, and other...

After Novo Nordisk A/S' (NYSE:NVO) launch of the first oral GLP-1 weight-loss drug, the spotlight at the JPMorgan Healthcare Conference turned sharply toward obesity treatments and what comes next for the rapidly expanding market. Citing an interview at the conference, CNBC on Wednesday said Ray...

Novo Nordisk A/S' (NYSE:NVO) weight-loss revolution just swallowed a record. In just its second week on the market, Novo Nordisk's oral Wegovy pill hit 20,371 prescriptions, up from 4,289 in week one—a nearly 500% week-over-week surge. For context, Eli Lilly And Co's (NYSE:LLY) Zepbound hit about...

Novo Nordisk A/S’ (NYSE:NVO) stock is trading higher on Friday as the Wegovy (semaglutide) pill hit 3,071 U.S. prescriptions in the first four days after its launch, Reuters noted, citing IQVIA data. Performance Data Wegovy pill showed an average weight loss of about 17% (16.6%) when...

Structure Therapeutics Inc. (NASDAQ:GPCR) is still months away from seeking approval for its experimental weight-loss pill, but the company is already bracing for a challenge that has plagued the obesity drug market: compounded copycat versions. Structure Therapeutics is advancing the oral small...

At a J.P. Morgan Healthcare Conference on Monday, Amgen Inc.(NASDAQ:AMGN) CEO Robert Bradway shared findings from part 2 of the Phase 2 Study of MariTide, its investigational obesity treatment. • Amgen stock is showing positive momentum. What’s the outlook for AMGN shares? Key Findings...

The U.S. Food and Drug Administration (FDA) on Tuesday said its preliminary review has not found evidence that glucagon-like peptide-1 receptor agonists, commonly known as GLP-1 RAs, cause suicidal thoughts or actions. Current prescribing information for GLP-1 drugs, including Eli Lilly and Co....

On Thursday, Eli Lilly and Co. (NYSE:LLY) revealed topline results from the novel TOGETHER-PsA open-label Phase 3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone for active psoriatic arthritis (PsA) and obesity or overweight with at...

, Inc. (NASDAQ:ARWR) on Tuesday shared interim results from two Phase 1/2a trials of ARO-INHBE and ARO-ALK7, the company’s investigational RNA interference (RNAi) therapeutics for obesity. Preliminary results showed meaningful reductions in multiple key measures, including visceral fat, total...

Redhill Biopharma Ltd (NASDAQ:RDHL) stock is trading lower on Tuesday, possibly on profit-taking after the stock rallied roughly 36% on Monday, as per data from Benzinga Pro. On Monday, RedHill Biopharma shared development progress for RHB-102 (Bekinda) in multiple gastrointestinal (GI) indications...

Novo Nordisk A/S (NYSE:NVO) on Monday said the Wegovy pill is now available, which was approved in December 2025. Novo Nordisk stock is charging ahead with explosive momentum. What’s fueling NVO momentum? Wegovy pill showed an average weight loss of about 17% (16.6%) when used along...